Semester Two Final Examinations, 2018 STAT1201 Analysis of Scientific Data Venue Solutions AC THE UNIVERSITY OF QUEENSLAND AUSTRALIA Seat Number Student Number Family Name This exam paper must not be removed from the venue First Name School of Mathematics & Physics EXAMINATION Semester Two Final Examinations, 2018 STAT1201 Analysis of Scientific Data This paper is for St Lucia Campus, Gatton Campus (External) and Gatton Campus students. Examination Duration: 120 minutes Reading Time: 10 minutes Exam Conditions: This is a Central Examination This is a Closed Book Examination - specified materials permitted During reading time - Write only on rough paper provided This examination paper will be released to the Library Materials Permitted In The Exam Venue: 4 (No electronic aids are permitted e.g. laptops, phones) Calculators - Casio FX82 series or UQ approved (labelled) An annotated copy of A Portable Introduction to Data Analysis (any edition) is also permitted. Materials To Be Supplied To Students: None Instructions To Students: For Examiner Use Only Question Mark 1 13 2 11 3 12 14 Total 50 There are 50 marks available on this exam from 4 questions. Write your answers in the spaces provided in pages 2-14 of this examination paper. Show your working and state conclusions where appropriate. Pages 15-19 give formulas and statistical tables. Those pages will not be marked. The textbook can have any amount of annotation on its pages. Loose sheets of paper or post-it notes are not permitted. Page tabs are allowed. Page 1 of 19
Semester Two Final Examinations, 2018 STAT1201 Analysis of Scientific Data Question 1 13 marks A recent study aimed to evaluate the clinical effects of the drug rivastigmine on the symptoms of schizophrenia when used alongside standard antipsychotic medication. A total of 36 patients with a diagnosis of schizophrenia entered into a 12-week, double- blind, clinical trial with random assignment to rivastigmine or placebo. Scores on the Mini Mental State Examination (MMSE) before and after the trial were used as the primary outcome measure. (a) The baseline MMSE score for the 18 patients in the rivastigmine group had a mean of 24.1 and a standard deviation of 2.9 while the 18 patients in the placebo group had a mean MMSE score of 23.0 and a standard deviation of 3.2. Does this give any evidence of a difference in the baseline MMSE scores between the two groups? State the null and alternative hypotheses, and use an appropriate test statistic to determine the P-value. What do you conclude? [5 marks] Let 11 = mean base line for placebo group M2 = - -11 rivastigmine group. Test Ho: M1=M2 VS HiMe, FM, using ty= (24.1-23.0) - 0 2.92 3.227 C 18 + 18 with df = min (n1-1, n2-1)=17. 1.1 1.02 === 1.08, P-value is 2xP(T17 7, 1.08) >0.2, so no evidence of a difference in mean baseline MUSE score between the groups. (b) Interpret your conclusion from (a) in the context of the random assignment to groups. [1 mark] This is what we would